

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# **EPS Creative Health Technology Group Limited**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock code: 3860)

## **UPDATE ANNOUNCEMENT ON DISCLOSEABLE TRANSACTION ACQUISITION OF THE ISSUED SHARE CAPITAL; AND SUBSCRIPTION OF CONVERTIBLE BONDS OF THE TARGET COMPANY**

Reference is made to the announcements (the “**Announcements**”) of EPS Creative Health Technology Group Limited (the “**Company**”) dated 29 November 2023 and 18 December 2023 in relation to the entering into the Share Transfer Agreement and the subscription for Convertible Bonds. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

The Board is pleased to announce that on 29 January 2024, (i) the Second Closing Conditions have been fulfilled; (ii) the share transfer pursuant to the Share Transfer Agreement and the subscription of the Convertible Bonds have been completed; (iii) the Company, through its wholly-owned subsidiary (i.e. EPS Innovative Medicine), purchased the Target company’s shares from the Vendor and converted the Convertible Bonds into share capital of the Target Company; and (iv) immediately following the conversion of Convertible Bonds, the Company is indirectly holding 51.0% of the issued share capital of the Target Company and the Target Company will become a subsidiary of the Company and the financial results, assets and liabilities of the Consortium will be consolidated into the financial statements of the Group.

By order of the Board  
**EPS Creative Health Technology Group Limited**  
**Miyano Tsumoru**  
*Executive Director*

Hong Kong, 29 January 2024

*As at the date of this announcement, the executive Directors are Mr. Shimada Tatsuji, Mr. Miyano Tsumoru, Mr. Maezaki Masahiro, Mr. Haribayashi Keikyo, Mr. Miyazato Hiroki and Mr. Chiu Chun Tak; the non-executive Directors are Mr. Kusaba Takuya and Mr. Yan Ping; and the independent non-executive Directors are Mr. Chan Cheuk Ho, Mr. Taguchi Junichi, Mr. Choi Koon Ming and Mr. Saito Hironobu.*